RPI-1

RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity[1].

Product Specifications

CAS Number

[269730-03-2]

UNSPSC

12352005

Hazard Statement

H400

Target

RET

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rpi-1.html

Purity

99.29

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C1NC2=C(C=C(OC)C(OC)=C2)/C1=C/C3=CC=C(O)C=C3

Molecular Formula

C17H15NO4

Molecular Weight

297.31

Precautions

P273-P391-P501

References & Citations

[1]Lanzi C, et al. Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci. 2003;60 (7) :1449-1459.|[2]Cuccuru G, et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst. 2004;96 (13) :1006-1014.